Neoleukin Therapeutics Inc expected to post a loss of 30  cents a share - Earnings Preview

Neurogene

06/05/2022 21:02

* Neoleukin Therapeutics Inc  NLTX.OQ   NLTX.O  is expected
to show no change in quarterly revenue when it reports 
results on May 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for Neoleukin
Therapeutics
Inc is for a loss of 30 cents per share. For the same quarter
last year, the company reported a loss of 27 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $20​, above​ its last closing price
of $1.31. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.30       -0.30      -0.28     Beat    6.9
 Sep. 30 2021  -0.28       -0.28      -0.28     Met     -0.6
 Jun. 30 2021  -0.27       -0.26      -0.27     Missed  -3.1​
 Mar. 31 2021  -0.23       -0.23      -0.27     Missed  -18.4
 ​​Dec.        -0.19       -0.25      -0.24     Beat    4.6
 31 2020                                                
 Sep. 30 2020  -0.20       -0.22      -0.19     Beat    13.6​
 Jun. 30 2020  -0.21       -0.21      -0.20     Beat    4.8
 Mar. 31 2020  -0.24       -0.24      -0.18     Beat    23.7
 This summary was machine generated May 6 at 20:02 GMT.  All
figures in US dollars  unless otherwise stated